1. Committee for Medicinal Products for Human Use (CHMP) (2005) The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (CHMP/ICH/423/02) (ICH S7B). European Medicines Agency, London, November 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf [Accessed on 15 May 2015]
2. Committee for Medicinal Products for Human Use (CHMP) (2005) ICH E14 Note for guidance on: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04) (ICH E14). European Medicines Agency, London, November 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf [Accessed on 15 May 2015]
3. Committee for Medicinal Products for Human Use (CHMP) (2012) ICH Topic E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions and answers (EMA/CHMP/ICH/310133/2008). European Medicines Agency, London, May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002878.pdf [Accessed on 15 May 2015]
4. ICH E14 Implementation Working Group (2014) ICH E14 Guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. questions & answers (R2). International Conference on Harmonisation, Geneva, March 2014. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_QAs_R2_Step4.pdf [Accessed on 15 May 2015]
5. Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H (2012) The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther 91:281–288